Navigation Links
Arno Therapeutics Announces Appointment of Brian Lenz, CPA as Chief Financial Officer
Date:8/14/2008

1 inhibitor that blocks the PI3K/Akt pathway undergoing IND-enabling studies. AR-42 is an orally available, targeted inhibitor of the Pan-DAC and Akt pathways also undergoing IND-enabling studies. Arno is actively pursuing additional compounds to expand its portfolio. For more information on Arno please visit http://www.arnothera.com.

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 that involve substantial risks and uncertainties. All statements, other than statements of historical facts, included in this press release regarding our strategy, future operations, outlook, milestones, the success of Arno's product development, future financial position, future financial results, plans and objectives of management are forward-looking statements. We may not actually achieve these plans, intentions or expectations and Arno cautions investors not to place undue reliance on our forward-looking statements. Actual results or events could differ materially from the plans, intentions and expectations disclosed in the forward-looking statements we make. Various important factors that could cause actual results or events to differ materially from the forward-looking statements that we make are described in greater detail in the reports we file with Securities and Exchange Commission, including those described under the caption "Risk Factors" in our Current Report on Form 8-K filed with the Securities and Exchange Commission on June 9, 2008. Arno is providing this information as of the date of this press release and does not undertake any obligation to update any forward-looking statements as a result of new information, future events or otherwise.


'/>"/>
SOURCE Arno Therapeutics, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. BN ImmunoTherapeutics Announces Partnership With National Cancer Institute
2. Amsterdam Molecular Therapeutics Reports Half Year Results 2008
3. Repair Stem Cell Institute Announces Industrys First Standards of Excellence for Global Stem Cell Treatment Centers to Protect Patients from Less-than-Competent Therapeutics
4. Halozyme Therapeutics Reports 2008 Second Quarter Financial Results
5. Orexigen(R) Therapeutics Schedules Webcast Discussion of Financial Results for the Second Quarter Ended June 30, 2008
6. IBC Life Sciences Kicks Off the 13th Annual Drug Discovery & Development of Innovative Therapeutics World Congress in Boston, Massachusetts
7. VIA Pharmaceuticals to Present at 13th Annual IBC Life Sciences Drug Discovery & Development of Innovative Therapeutics World Congress
8. CV Therapeutics Reports 2008 Second Quarter Financial Results
9. Horizon Therapeutics Announces Corporate Relocation to the Chicago Area
10. Amicus Therapeutics Announces Second Quarter 2008 Results Release Date
11. Cardinal Health, Prime Therapeutics Sign Primary Distribution Agreement
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/19/2014)... 18, 2014 Ed Bilsky, Ph.D., vice ... Center for Excellence in the Neurosciences (CEN), and professor ... been selected as a member of the prestigious Dana ... neuroscientist from Maine to receive this honor. , ... entirely by the Dana Foundation. Its mission is ...
(Date:12/19/2014)... In contrast to traditional LED lights where the spectrum ... proprietary LED technology to incorporate their spectra in a ... critical in low proximity installations. The Valoya L-series offers ... which is up to four times longer than commonly ... was clearly higher when compared to traditional fluorescent or ...
(Date:12/19/2014)...  Decision Resources Group finds that the ... moderately through 2023 as the aging population, increasing adoption ... biomaterials all spur procedure volumes. Growth will be particularly ... and India , where ... for a larger proportion of the population. ...
(Date:12/19/2014)... Dec. 18, 2014 Relmada Therapeutics, Inc. (OTCQB: ... treatment of chronic pain, announced the results of its ... "This was a transformational year in Relmada,s history and ... our company," said Sergio Traversa , chief executive ... executed on key financial, human resource and clinical development ...
Breaking Biology Technology:UNE's Ed Bilsky Named Member of Dana Alliance for Brain Initiatives 2UNE's Ed Bilsky Named Member of Dana Alliance for Brain Initiatives 3Asia Pacific Dental Biomaterial Market Will Grow Strongly Through 2023 2Asia Pacific Dental Biomaterial Market Will Grow Strongly Through 2023 3Relmada Therapeutics Announces Results of Annual Shareholders Meeting 2
... Uroplasty, Inc. (NASDAQ: UPI ), a ... proprietary products to treat voiding dysfunctions, announced today that ... President and CFO, will present the Company,s business strategy ... Conference at 2:10 PM ET on Tuesday, December 13, ...
... Conn., Dec. 6, 2011 Biodel Inc. (Nasdaq: ... ended September 30, 2011. Fourth Quarter Operating ... 2011, the company: Selected a new lead ... a Phase 1 clinical trial; Extended an agreement with ...
... Pharmaceuticals, Inc. (NASDAQ:   QCOR) announced today that executive ... be held on December 13-14, 2011 in New York.  ... scheduled to present an overview of the Company on ... A live webcast and subsequent archived replay ...
Cached Biology Technology:Uroplasty to Present at the Oppenheimer 22nd Annual Healthcare Conference 2Biodel Reports Fourth Quarter Fiscal Year 2011 Financial Results 2Biodel Reports Fourth Quarter Fiscal Year 2011 Financial Results 3Biodel Reports Fourth Quarter Fiscal Year 2011 Financial Results 4Biodel Reports Fourth Quarter Fiscal Year 2011 Financial Results 5Biodel Reports Fourth Quarter Fiscal Year 2011 Financial Results 6Questcor Pharmaceuticals to Present at the Oppenheimer Healthcare Conference on December 13, 2011 2
(Date:12/4/2014)... GARDENS, Fla. , Dec. 3, 2014 /PRNewswire/ ... solutions, today announced that its DigitalPersona ® ... fingerprint readers have been deployed throughout First Bank ... , South Carolina and ... in Southern Pines, North Carolina ...
(Date:11/21/2014)... Calif. , Nov. 20, 2014 Strict ... driver efficiency are piloting the North American and European ... of accidents growing, gesture recognition systems that are intuitive ... a mark in the industry. New ... Automotive Gesture Recognition Market in Europe ...
(Date:11/18/2014)... BETHESDA, Md. , Nov. 17, 2014 The ... European and U.S. regulatory agencies will speak and at least ... Quality Metrics Conference at the Omni Shoreham Hotel in ... is pleased once again to have significant support from the ... and Europe in our effort to ...
Breaking Biology News(10 mins):First Bank Partners with Crossmatch to Increase Log In Security 2First Bank Partners with Crossmatch to Increase Log In Security 3Gesture Recognition Intensifies with the Rise of In-car Smartphone Integration, Says Frost & Sullivan 2Gesture Recognition Intensifies with the Rise of In-car Smartphone Integration, Says Frost & Sullivan 3Gesture Recognition Intensifies with the Rise of In-car Smartphone Integration, Says Frost & Sullivan 4FDA's Janet Woodcock, EMA's Emer Cooke Headline PDA Quality Metrics Conference 2
... may one day reap the benefits of research at the ... can be used to make new tendon or ligament tissue. ... challenge to orthopedic medicine. In the United States, at ... Moreover, the intervertebral disc, which is composed in part of ...
... activity of a key brain cell receptor involved in ... mice engineered to have pathological hallmarks of the disease. ... the pathologies--the brain-clogging buildup of protein "amyloid plaque" outside ... cells. , In an article in the March ...
... to neural stem cells derived from bone marrow, researchers ... developed a tool to track and kill malignant brain ... , Results of an animal study are published in ... the researchers are now applying to regulatory agencies to ...
Cached Biology News:Stem cells can repair torn tendons or ligaments 2Experimental drug reverses key cognitive deficits, pathology in Alzheimer's 2Marrow-derived stem cells deliver new cytokine to kill brain tumor cells, offer protection 2Marrow-derived stem cells deliver new cytokine to kill brain tumor cells, offer protection 3
...
... The VSO LF (Low Flow) offers the same ... control for applications where control is critical or ... solenoid-operated valve automates the flow of gas in ... either DC current or pulse width modulation; closed ...
Hamster Serum; U.S. sourced, ideal for those who seek an uncompromising quality. Low Hemoglobin levels; U.S. sourced, ideal for those who seek an uncompromising quality. Low Hemoglobin levels....
... cDNA Labeling Kit with CyScribe GFX ... generation and purification of Cy3- and ... for complete cDNA labeling and purification.Flexible ... for performing labeling reactions with either ...
Biology Products: